Halozyme’s FY2025 Royalties Up 52%, Forecasts 30-35% Growth and Licenses Hypercon to Oruka
Halozyme’s FY2025 royalty revenue climbed 52% to $867.8 million, and it forecast 30-35% royalty growth with adjusted EBITDA of $1.125-1.205 billion for 2026. It licensed Hypercon technology to Oruka for ORKA-001 in psoriasis, acquired Hypercon and Surf Bio platforms, and added partnerships with Vertex and Takeda.
1. FY2025 Financial Performance
Halozyme reported FY2025 royalty revenue of $867.8 million, up 52% year over year, driven by expanded use of its ENHANZE delivery platform across ten commercialized products and increased subcutaneous adoption by partner companies.
2. 2026 Financial Guidance
The company projects royalty growth of 30-35% for 2026 and an adjusted EBITDA range of $1.125 billion to $1.205 billion, reflecting contributions from new collaborations and expanded delivery offerings.
3. Oruka Collaboration Details
Halozyme’s subsidiary granted Oruka exclusive global rights to Hypercon microparticle technology for ORKA-001 targeting IL-23p19 in psoriatic disease, plus an option on a second target, with upfront and development milestone payments and mid-single-digit royalties on net sales.
4. Platform Expansion and Partnerships
Halozyme broadened its delivery technology portfolio by acquiring Hypercon and Surf Bio platforms and securing partnerships with Vertex and Takeda, extending its intellectual property runway and reinforcing its position as a comprehensive biologics delivery solutions provider.